Different Expression and Function of the Endocannabinoid System in Human Epicardial Adipose Tissue in Relation to Heart Disease

Canadian Journal of Cardiology

Volumn 29, Issue 4, 2013, Pages 499-509

  Cappellano, Giuseppe ^a   Uberti, Francesca ^a   Caimmi, Philippe Primo ^b   Pietronave, Stefano ^a   Mary, David A S G ^a   Dianzani, Chiara ^c   Micalizzi, Ezio ^b   Melensi, Matteo ^a   Boldorini, Renzo ^a   Nicosia, Gabriella ^a   Crosio, Enrico ^a   Chiocchetti, Annalisa ^a   Aina, Franco ^d   Prat, Maria ^a   Dianzani, Umberto ^a   Vacca, Giovanni ^a   Ariatti, Cristiano ^d   Grossini, Elena ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Cardiac Surgery Unit   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Cardiac Rehabilitation Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AMIDASE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C; PROTEIN KINASE C;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS SURGERY; EPICARDIUM; FEMALE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART VALVE SURGERY; HUMAN; HUMAN TISSUE; MALE; PROADIPOCYTE; REPERFUSION INJURY; UPREGULATION; WESTERN BLOTTING;

ADIPOCYTES; ADIPOSE TISSUE; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BLOTTING, WESTERN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOCANNABINOIDS; ENZYME ACTIVATION; ETHYLENEDIAMINES; FEMALE; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PERICARDIUM; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROKE VOLUME; SULFANILAMIDES; UP-REGULATION;

EID: 84875627847     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.06.003     Document Type: Article

References (42)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
2. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sci 2005, 78:549-563.
3. Roche R., Hoareau L., Bes-Houtmann S., et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Bio 2006, 126:177-187.
4. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008, 51:1356-1367.
5. Howlett A.C., Barth F., Bonner T.I., et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
6. Galiègue S., Mary S., Marchand J., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
7. Weis F., Beiras-Fernandez A., Sodian R., et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 2010, 48:1187-1193.
8. Lépicier P., Lagneux C., Sirois M.G., Lamontagne D. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci 2007, 81:1373-1380.
9. Shmist Y.A., Goncharov I., Eichler M., et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 2006, 283:75-83.
10. Wagner J.A., Járai Z., Bátkai S., Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 2001, 423:203-210.
11. Baker A.R., Silva N.F., Quin D.W., et al. Human epicardial adipose tissue espresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006, 5:1.
12. Sugamura K., Sugiyama S., Nozaki T., et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009, 119:28-36.
13. Rajesh M., Mukhopadhyay P., Bátkai S., et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010, 56:2115-2125.
14. Lépicier P., Bouchard J.F., Lagneux C., Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003, 139:805-815.
15. González C., Herradón E., Abalo R., et al. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes Metab Res Rev 2011, 27:331-340.
16. Iacobellis G., Bianco A.C. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011, 22:450-457.
17. Mazurek T., Zhang L., Zalewski A., et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108:2460-2466.
18. Baker A.R., Silva N.F., Quinn D.W., et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006, 5:1-7.
19. Fain J.N., Sacks H.S., Bahouth S.W., Tichansky D.S., Madan A.K., Cheema P.S. Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. Metabolism 2010, 59:1379-1386.
20. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
21. Fernyhough M.E., Vierck J.L., Hausman G.J., et al. Primary adipocyte culture: adipocyte purification methods may lead to a new understanding of adipose tissue growth and development. Cytotechnology 2004, 46:163-172.
22. Grossini E., Molinari C., Caimmi P.P., Uberti F., Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009, 156:250-261.
23. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
24. Pacher P., Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 2009, 31:63-77.
25. Caraceni P., Pertosa A.M., Giannone F., et al. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 2009, 58:1135-1143.
26. Wagner J.A., Abesser M., Harvey-White J., Ertl G. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 2006, 47:650-655.
27. Pacher P., Mukhopadhyay P., Mohanraj R., Godlewski G., Batkai S., Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008, 52:601-607.
28. Di Marzo V., Cote M., Matias I., et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009, 52:213-217.
29. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?. Arterioscler Thromb Vasc Biol 2009, 29:7-9.
30. Iacobellis G., Malavazos A.E., Corsi M.M. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol 2011, 43:1651-1654.
31. 1 receptor activation. Endocrinology 2010, 151:5882-5892.
32. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997, 17:5327-5333.
33. Lagneux C., Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 2001, 132:793-796.
34. Soskić S.S., Dobutović B.D., Sudar E.M., et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance. Open Cardiovasc Med J 2011, 5:153-163.
35. Razavi H.M., Hamilton J.A., Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005, 106:147-162.
36. Rajesh M., Mukhopadhyay P., Haskó G., Liaudet L., Mackie K., Pacher P. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 2010, 160:688-700.
37. Mukhopadhyay P., Rajesh M., Bátkai S., et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010, 85:773-784.
38. Liu J., Batkai S., Pacher P., et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003, 278:45034-45039.
39. Szmitko P.E., Verma S. The endocannabinoid system and cardiometabolic risk. Atherosclerosis 2008, 199:248-256.
40. Mukhopadhyay P., Rajesh M., Pan H., et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 2010, 48:457-467.
41. Hausenloy D.J., Tsang A., Mocanu M.M., Yellon D.M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005, 288:H971-H976.
42. Mukhopadhyay P., Horváth B., Rajesh M., et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 2011, 50:179-195.